- Teriflunomide
Drugbox
IUPAC_name = (Z)-2-Cyano-3-hydroxy-N- [4-(trifluoromethyl)phenyl] -2-butenamide
CAS_number = 163451-81-8
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 5479847
DrugBank =
chemical_formula =
C=12 | H=9 | F=3 | N=2 | O=2
molecular_weight = 270.207 g/mol
smiles = N#CC(=C(/C)O)C(=O)Nc1ccc(C(F)(F)F)cc1
bioavailability =
protein_bound = >99.3%
metabolism =
elimination_half-life = 2 weeks
excretion = Biliar, renal
pregnancy_AU =
pregnancy_US =
pregnancy_category= X (contraindicated)
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = OralMechanisms of action
Teriflunomide is an
immunomodulatory drug inhibiting pyrimidinede novo synthesis by blocking the enzymedihydroorotate dehydrogenase . It is uncertain whether this explains its effect on MS lesions. [cite journal
author = H. Spreitzer
date =March 13 ,2006
title = Neue Wirkstoffe - Teriflunomid
journal = Österreichische Apothekerzeitung
issue = 6/2006
language = German ]It has been found that teriflunomid blocks the transcription factor
NF-κB . It also inhibitstyrosine kinase enzymes, but only in high doses not clinically used. [cite journal|last=Breedveld|first=FC|coauthors=Dayer, J-M|date=November 2000|title=Leflunomide: mode of action in the treatment of rheumatoid arthritis|journal=Ann Rheum Dis|volume=59|pages=841 - 849]Activation of leflunomide to teriflunomide
The structure which results from ring opening can interconvert between the "E" and "Z"
enol ic forms (and the corresponding keto-amide), with the "Z" enol being the most stable and therefore most predominant form.ee also
See
Leflunomide for information on pharmacokinetics, side-effects, contraindications and other data.References
Wikimedia Foundation. 2010.